Elena Chernomordikov

Elena Chernomordikov

Auto-generated profile, based on publicly available information

Elena Chernomordikov


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2023 in Life
Verified
Journal Article
Open access
PDF file
Walid ShalataWalid Shalata
Walid Shalata
ismaell masalhaismaell masalha
ismaell masalha
SIShlomo Yaron Ishay
Shlomo Yaron Ishay
ECElena Chernomordikova
Elena Chernomordikova
AJAshraf Abu jama
Ashraf Abu jama
AYAlex Yakobson
Alex Yakobson
In this particular case study, we present a 66-year-old male who was diagnosed with an atrial myxoma eight years after receiving treatment for non-small cell lung cancer. The patient underwent chemo-radiotherapy (mediastinal area) in 2012 to address stage III-A adenocarcinoma of the lung. During follow-up imaging in 2020, a left atrial mass displaying characteristic features of a cardiac myxoma was detected. Upon reviewing a computed tomographic (CT) scan from 2017 within the previously irradiated mediastinal region, the cardiac mass was retrospectively identified. The surgical excision of the cardiac mass was performed, and a subsequent pathological examination confirmed the diagnosis of myxoma. To the best of our knowledge, this is the first reported case of a left atrial myxoma in a patient previously treated for adenocarcinoma of the lung and the first instance of an atrial myxoma occurring in a site that had undergone prior radiation therapy.

15 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
KRKeren Rouvinov
Keren Rouvinov
AYAlexander Yakobson
Alexander Yakobson
ATAngela Tiganas
Angela Tiganas
NSNoa Shani Shrem
Noa Shani Shrem
ECElena Chernomordikov
Elena Chernomordikov
Walid ShalataWalid Shalata
Walid Shalata
Background: Invasive BC patients are at risk of loco-regional recurrence, distant MTS, and the development of second primary tumors. SPMs comprise the sixth most common group of malignancies. Material and methods: The records of 125 consecutive patients with primary invasive TCC of the bladder seen in the Oncology Department of Soroka University Medical Center were reviewed between January 2016 and December 2023. We recorded demographic details, the type of primary treatment, tumor site, time to diagnosis of MTS, and occurrence of SPMs. Results: The primary treatments included RC in 58 patients (median age 66 years, range 43–86), PC in 9 patients (median age 64 years, range 22–73), and XRT in 23 patients (median age 74 years, range 22–87). Five patients from the PC group were also treated by XRT. A total of 90 (72%) patients developed MTS or SPMs, with 66 of these developing MTS and 24 developing SPMs. The median age was 70 years (range 22–87). The most frequent site of MTS was in the pelvic LNs (34 patients), followed by bone (18 patients), liver (8 patients), and lung (6 patients), with 4 patients developing synchronous MTS in the pelvic LNs and liver. The median time from diagnosis to MTS was 14.3 months. The distribution of MTS varied according to primary treatment. After RC, 17 patients developed LN MTS, 7 liver, 6 bone, and 3 lung MTS. The average times for developing MTS were as follows: LNs, 14.8 months, liver, 59.7 months, bone, 6.8 months, and lung, 16 months. Following XRT, LN MTS developed in 17 patients: 12 bone, 3 lung, and 1 liver. The most frequent SPMs were prostate cancer with 11 patients and lung cancer with 6 patients, with the median time from TCC diagnosis of 54 months. Conclusion: A regular extended follow-up for invasive BC patients is vital to ensure the early detection of frequently occurring MTS and SPMs. Through the early diagnosis of local recurrences, MTS, and SPMs, treatment results and patient prognosis can be significantly improved.

1 March 2023
Verified
Journal Article
Closed access
ECElena Chernomordikov
Elena Chernomordikov
KRKeren Rouvinov
Keren Rouvinov
WMWilmosh Mermershtain
Wilmosh Mermershtain
KLKonstantin Lavrenkov
Konstantin Lavrenkov